5th RNA Editing Summit

Welcome to the 5th RNA Editing Summit
Pioneering RNA Editing Drugs Towards Clinical Realities
Despite remarkable advancements, such as Wave Life Sciences pioneering the first clinical candidate and significant investments like Ascidian Therapeutics securing $40 million for their RNA editing pipeline, challenges persist in optimizing delivery and ensuring treatment longevity for new RNA editing therapies.

Scheduled for June 2024, the 5th RNA Editing Summit is set to address these obstacles head-on. Our updated agenda features fresh content and an enhanced pre-conference focus day, spotlighting innovative platforms and strategies for targeting beyond the liver. Explore the latest breakthroughs in ADAR editing, RNA trans-splicing, gRNA-free editing, and RADAR technology.

Join leading companies like Wave Life Sciences, Korro Bio, Shape Therapeutics, AIRNA, Amber Bio, Edigene, and more as we convene industry experts and thought leaders. With over 80 technical and strategic minds coming together, this summit promises data-driven presentations and interactive discussions to propel RNA editing therapeutics through the clinic and toward regulatory approval.

Don't miss this opportunity to be at the forefront of RNA editing innovation. Secure your spot at the 5th RNA Editing Summit today!

URLs:
Tickets: https://go.evvnt.com/2221213-2?pid=91
Brochure: https://go.evvnt.com/2221213-3?pid=91

Prices:
Drug Developer - Conference Only: USD 2999.00,
Drug Developer - Conference + Focus Day: USD 4197.00,
Academic - Conference Only: USD 2599.00,
Academic - Conference + Focus Day: USD 3597.00,
Vendor - Conference Only: USD 3699.00,
Vendor - Conference + Focus Day: USD 5097.00

Speakers: Andrew Fraley, Chief Technology Officer, Entrepreneur In Residence, Judo Bio, Atlas Venture, C. Anthony Altar, President and Chief Operating Officer, Splice Therapeutics, Channabasavaiah Gurumurthy, Professor, Nebraska Medical Center, Cynthia Caracta, Executive Medical Director, Wave Life Sciences, David Huss, Chief Scientific Officer, Shape Therapeutics, Dimitra Dafou, Associate Professor, Aristotle University of Thessaloniki, Eerik Kaseniit, Chief Scientific Officer, Radar Therapeutics, Ginnie Yang, Senior Vice President, Translational Medicine, Wave Life Sciences, Jacob Borrajo, Co-Founder and Chief Executive Officer, Amber Bio, Kenneth Longo, Vice President - Discovery Data Science, Wave Life Sciences, Kris Elverum, Chief Executive Officer, AIRNA, Lenka Van Sint Fiet, Senior Director, Technology, ProQR Therapeutics, Lina Bagepalli, Scientist II, Shape Therapeutics, Mao Taketaniz, Director, Synthetic Biology, Jorna Therapeutics, Pengfei Yuan, Chief Technology Officer, EdiGene, Philipp Reautschnig, Academic Researcher, University of Tuebingen, Rob Shaffer, Co-Founder and Chief Operating Officer, Vrata Therapeutics, Ron Weiss, Professor, Massachusetts Institute of Technology, Saul Martinez, Montero Senior Director, RNA Therapeutics, Dyne Therapeutics, Sourav Choudhury, Laboratory Head, Sanofi, Steve Seedhouse, Managing Director, Biotechnology Equity Research Analyst, Raymond James, Venkat Krishnamurthy, Senior Vice President, Head Of Platform and RNA Editing, Korro Bio, Zeneng Wang, Chair, Professor, School of Life Sciences, Southern University of Science and Technology, Shenzhen